108,803,656 133,755,071 (24,951,415) (18.66) Net Profit (Loss) (72,320,514) (72,280,526) (39,988) (0.06) Earnings per share (Baht per share) (0.015) (0.016) 0.001 6.25 Net Profit (Loss) The Company and

)% Specialty Chemicals 40 158 (74)% 2 16 22 (90)% Core EBIT 598 1,000 (40)% 54 136 190 (72)% Core Net Profit after Tax and NCI4 387 789 (51)% 8 92 121 (93)% Core Net Profit after Tax and NCI (THB m) 12,002

subsidiaries (14.60) (9.03) 0.05 Profit(Loss) attributable to equity holders of the company (68.68) (42.47) (9.41) (38.21) (59.27) 629.86 Basic Loss Per Share (THB) (0.09) (0.02) Book Value per Share (THB) 0.46

1,494 8% EBITDA Bio-Based Product Business4/ 113 179 59 -48% -67% 259 238 -8% EBITDA Resource Business5/ 59 133 93 58% -30% 81 226 181% EBITDA Others 6/ (25) (25) (12) 54% 53% (25) (37) -48% Profit

million baht or 10.4 percent. The company reported profit for Q2/2017 of 4.9 million baht compared with reported loss for Q2/2016 of 6.1 million baht. For the six-month period of 2017, the consolidated

revenue for Q3/2017 of 95.0 million baht compared with Q3/2016 of 92.8 million baht, increased 2.2 million baht or 2.4 percent. The company reported profit for Q3/2017 of 4.7 million baht compared with

company reported loss for Q2/2018 of 6.2 million baht compared with reported profit for Q2/2017 of 4.9 million baht. For the six-month period of 2018, the consolidated revenue was 160.2 million baht

1,359 MB increased from 9M/2016 which was at 885 MB. However, the company’s performance was still impacted from Stock Loss and appreciating Baht currency which resulted in the reported net profit in

the media landscape brought by the change in people’s lifestyles and the way people consume media after the increasing popularity of mobile phones (or smartphones). Advertisers have adjusted their

trademark “Wuttisak Clinic”. 3. Analysis of Operating Results Profit & Loss Statements (MB) Consolidated Financial Statements 2017 2016 +/(-) % Revenues from sales and services . . . . % Gross profit from